{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:00:13Z","timestamp":1788382813949,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.semarthrit.2022.151996","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T11:43:41Z","timestamp":1647690221000},"page":"151996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"54","author":[{"given":"Anh","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-9334","authenticated-orcid":false,"given":"Quang A.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0001","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61","author":"Sieper","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"Suppl4","key":"10.1016\/j.semarthrit.2022.151996_bib0002","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/keaa422","article-title":"Non-radiographic versus radiographic axSpA: what's in a name?","volume":"59","author":"Michelena","year":"2020","journal-title":"Rheumatology"},{"issue":"10089","key":"10.1016\/j.semarthrit.2022.151996_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151996_bib0004","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s41927-019-0086-3","article-title":"Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016","volume":"3","author":"Walsh","year":"2019","journal-title":"BMC Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151996_bib0006","first-page":"763","article-title":"Ankylosing spondylitis: field in progress","volume":"14","author":"Slobodin","year":"2012","journal-title":"Isr Med Assoc J"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151996_bib0007","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ncprheum0297","article-title":"A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis","volume":"2","author":"Boonen","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0008","first-page":"e375","article-title":"Measuring health-related quality of life in adults with chronic conditions in primary care settings: critical review of concepts and 3 tools","volume":"62","author":"Hand","year":"2016","journal-title":"Can Fam Phys"},{"issue":"s1","key":"10.1016\/j.semarthrit.2022.151996_bib0009","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1524-4733.2009.00519.x","article-title":"The use of QALYs in clinical and patient decision-making: issues and prospects","volume":"12","author":"Kind","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.publhealth.20.1.309","article-title":"Health status assessment methods for adults: past accomplishments and future challenges","volume":"20","author":"McHorney","year":"1999","journal-title":"Annu Rev Public Health"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151996_bib0011","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","article-title":"Measuring health-related quality of life","volume":"118","author":"Guyatt","year":"1993","journal-title":"Ann Intern Med"},{"issue":"7351","key":"10.1016\/j.semarthrit.2022.151996_bib0012","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/bmj.324.7351.1417","article-title":"Quality of life measurement: bibliographic study of patient assessed health outcome measures","volume":"324","author":"Garratt","year":"2002","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-7525-2-32","article-title":"Patients' needs, satisfaction, and health related quality of life: towards a comprehensive model","volume":"2","author":"Asadi-Lari","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"7297","key":"10.1016\/j.semarthrit.2022.151996_bib0014","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.322.7297.1297","article-title":"Measuring quality of life: using quality of life measures in the clinical setting","volume":"322","author":"Higginson","year":"2001","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0016","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/1756-185X.13758","article-title":"Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea","volume":"23","author":"Lee","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151996_bib0017","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151996_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","article-title":"Biologics for treating axial spondyloarthritis","volume":"18","author":"Jones","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0019","doi-asserted-by":"crossref","DOI":"10.1007\/5584_2020_611","article-title":"Benefit of biological drugs for quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of clinical trials","author":"Ta\u0144ski","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151996_bib0020","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s11136-016-1345-z","article-title":"The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis","volume":"25","author":"Yang","year":"2016","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151996_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151996_bib0023","first-page":"S218","article-title":"Health-related quality of life-an introduction","volume":"13","author":"Khanna","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0024","unstructured":"RAND Corporation California, USA [Available from: https:\/\/www.rand.org\/ ]."},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151996_bib0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"24","key":"10.1016\/j.semarthrit.2022.151996_bib0026","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"A new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0028","first-page":"155","article-title":"[EuroQol-5D (EQ-5D): an instrument for measuring quality of life]","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch Chest Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151996_bib0029","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0030","unstructured":"EuroQol Research Foundation. EQ-5D user guide 2018 [Available from: https:\/\/euroqol.org\/publications\/user-guides ]."},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0031","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0032","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","article-title":"A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis","volume":"60","author":"Marra","year":"2005","journal-title":"Soc Sci Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0033","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0034","unstructured":"Galen-Research 2022 [Available from: http:\/\/www.galen-research.com\/home\/ ]."},{"key":"10.1016\/j.semarthrit.2022.151996_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-5-7","article-title":"Translation and validation of non-english versions of the Ankylosing spondylitis quality of life (ASQOL) questionnaire","volume":"5","author":"Doward","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0036","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4,. The Cochrane Collaboration. 2020."},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151996_bib0037","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0038","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151996_bib0039","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study","volume":"57","author":"Davis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151996_bib0040","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151996_bib0041","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0042","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0043","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.semarthrit.2022.151996_bib0044","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151996_bib0045","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active Ankylosing spondylitis: a phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0046","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active Ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0047","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with Ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151996_bib0048","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and Safety of Secukinumab 150 mg with and without loading regimen in Ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"10163","key":"10.1016\/j.semarthrit.2022.151996_bib0049","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151996_bib0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0051","article-title":"The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial","author":"Reveille","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"9313","key":"10.1016\/j.semarthrit.2022.151996_bib0052","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151996_bib0053","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0054","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7525-11-59","article-title":"Minimal clinically important differences for the EQ-5D and QWB-SA in post-traumatic stress disorder (PTSD): results from a doubly randomized preference trial (DRPT)","volume":"11","author":"Le","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/annrheumdis-2018-eular.5020","article-title":"FRI0208\u2005Ankylosing spondylitis quality of life: defining minimal clinically important change","volume":"77","author":"Richard","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151996_bib0056","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151996_bib0057","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2018-213590","article-title":"Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British society for rheumatology biologics register (BSRBR-AS) and meta-analysis","volume":"77","author":"Shim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151996_bib0058","first-page":"2883","article-title":"Secukinumab provides early and sustained improvements in health-related quality of life in patients with ankylosing spondylitis: a pooled analysis from the secukinumab phase 3 trial program","volume":"70","author":"Deodhar","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0059","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10067-020-05209-x","article-title":"Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action","volume":"40","author":"Rodrigues-Manica","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"Supplement_4","key":"10.1016\/j.semarthrit.2022.151996_bib0060","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1093\/rheumatology\/keaa250","article-title":"Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis","volume":"59","author":"Poddubnyy","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151996_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027354","article-title":"Impact of using patient-reported outcome measures in routine clinical care of paediatric patients with chronic conditions: a systematic review protocol","volume":"9","author":"Bele","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151996_bib0062","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/sim.1183","article-title":"Investigating causes of heterogeneity in systematic reviews","volume":"21","author":"Glasziou","year":"2002","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151996_bib0063","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jclinepi.2003.12.008","article-title":"Time-dependent bias was common in survival analyses published in leading clinical journals","volume":"57","author":"van Walraven","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151996_bib0064","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","article-title":"Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries","volume":"36","author":"Janssen","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jval.2017.11.007","article-title":"EQ-5D: moving from three levels to five","volume":"21","author":"Lloyd","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151996_bib0066","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151996_bib0067","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12955-019-1260-4","article-title":"Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study","volume":"18","author":"Dougados","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151996_bib0068","first-page":"1219","article-title":"Cost-effectiveness of treatment strategies with biologics in accordance with treatment guidelines for ankylosing spondylitis: A patient-level model","volume":"26","author":"Le","year":"2020","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:59Z","timestamp":1758733679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":68,"alternative-id":["S0049017222000476"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151996","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151996"}}